- Home
- RVYL vs BIAF Comparison
RVYL vs BIAF Comparison
Compare RVYL & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVYL
- BIAF
- Stock Information
- Founded
- RVYL 2007
- BIAF 2014
- Country
- RVYL United States
- BIAF United States
- Employees
- RVYL N/A
- BIAF N/A
- Industry
- RVYL Professional Services
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- RVYL Consumer Discretionary
- BIAF Health Care
- Exchange
- RVYL Nasdaq
- BIAF Nasdaq
- Market Cap
- RVYL 7.3M
- BIAF 7.6M
- IPO Year
- RVYL N/A
- BIAF 2022
- Fundamental
- Price
- RVYL $0.28
- BIAF $0.35
- Analyst Decision
- RVYL Hold
- BIAF Hold
- Analyst Count
- RVYL 1
- BIAF 1
- Target Price
- RVYL N/A
- BIAF N/A
- AVG Volume (30 Days)
- RVYL 5.1M
- BIAF 10.4M
- Earning Date
- RVYL 11-13-2025
- BIAF 11-13-2025
- Dividend Yield
- RVYL N/A
- BIAF N/A
- EPS Growth
- RVYL N/A
- BIAF N/A
- EPS
- RVYL N/A
- BIAF N/A
- Revenue
- RVYL $48,904,000.00
- BIAF $7,681,059.00
- Revenue This Year
- RVYL $27.50
- BIAF N/A
- Revenue Next Year
- RVYL $35.71
- BIAF $20.04
- P/E Ratio
- RVYL N/A
- BIAF N/A
- Revenue Growth
- RVYL N/A
- BIAF 4.99
- 52 Week Low
- RVYL $0.25
- BIAF $0.16
- 52 Week High
- RVYL $2.35
- BIAF $2.26
- Technical
- Relative Strength Index (RSI)
- RVYL 40.22
- BIAF 73.86
- Support Level
- RVYL $0.27
- BIAF $0.24
- Resistance Level
- RVYL $0.31
- BIAF $0.27
- Average True Range (ATR)
- RVYL 0.02
- BIAF 0.03
- MACD
- RVYL 0.00
- BIAF 0.01
- Stochastic Oscillator
- RVYL 17.20
- BIAF 54.52
About RVYL Ryvyl Inc.
Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.